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Other names: AMPK; AMPKb; AMPK beta; 






The PRKAB1 gene, with a total genomic size of 13639 
bp, is composed of 7 coding exons of varying lengths. 
Transcription 
The human PRKAB1 transcript has approximately 
2500-bp and contains an open reading frame of 813 
bases, resulting in a predicted protein of 270 amino 




PRKAB1 has a molecular mass of 30382 Da; This 
protein constitutes a regulatory subunit of the AMP-
activated protein kinase (AMPK). 
AMPK is an heterotrimer of an alpha catalytic, a beta 
and a gamma non-catalytic regulatory subunits, each 
encoded by two or three distinct genes (AMPKalpha1 –  
AMPKalpha2; AMPKbeta1 - AMPKbeta2; 
AMPKgamma1 - AMPKgamma2 - AMPKgamma3) 
which have varying tissue and subcellular expression. 
Post-translational modifications of PRKAB1 include 
myristoylation and phosphorylation in vivo at 
Ser24/25, Ser108 and Ser182. Phosphorylation at 
Ser108 is required for the activation of the AMPK 
enzyme, whereas phosphorylation at Ser24/25 and 
Ser182 affects the localization of the complex. 
Expression 
AMPKbeta1 protein expression is highest in the liver, 
and testis and low in kidney and skeletal muscle. In 
contrast, expression of PRKAB2, encoded by a 
different gene, is higher in skeletal muscle. This 
indicates a tissue specific pattern of expression of these 
two regulatory beta subunits. 
Localisation 
AMPKbeta1 localises in the cytoplasm. However 
nuclear translocation is possible because mutations of 
Ser24/25 and Ser182 to alanine lead to the 
redistribution of PRKAB1 to the nucleus. 
Function 
AMPKbeta1, may act as a positive regulator of AMPK 
activity and it may serve as an adaptor molecule for the 
catalytic subunit. It has also been reported that 
AMPKbeta1 contains a glycogen-binding domain 




PRKAB1 gene structure. UTR: untranslated region. 
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The heterotrimeric protein AMPK senses low 
intracellular energy levels upon increased in the 
AMP/ATP ratio. Binding of AMP results in allosteric 
activation, inducing phosphorylation on Thr-172 of the 
AMPKa regulatory subunit (PRKAA) by LKB1 in 
complex with STE20-related adapter-alpha (STRAD 
alpha). AMPK activation leads to the modulation of the
activity of multiple downstream targets to normalize 
ATP levels. 
Among these substrates is the tuberin protein, the 
product of the tuberous sclerosis complex 2 gene 
(TSC2) that upon activation by AMPK represses the 
activity of the mammalian target of rapamycin, mTOR. 
It has been reported that PRKAB1 and PRKAB2 
contain a glycogen binding domain that targets AMPK 
to glycogen. 
Moreover, it has been shown that expression of 
PRKAB1 and PRKAB2 genes, in human cells, may be 
mediated by p53. 
Homology 
There is a AMPKbeta1 isoform, designated 
AMPKbeta2, encoded by the PRKAB2 gene. The N-
terminal region of beta2 differs significantly from that 
AMPKbeta1 isoform, suggesting that this region could 
play a role in isoform-specific AMPK activity. 
The AMPKbeta subunit is the mammalian homolog of 
the S. cerevisiae Sip1p/Sip2p/Gal83p family of proteins 
that interact with the AMPKa homolog, Snf1p, and are
involved in glucose regulation of gene expression. 
Mutations 
Note: No germ-line or somatic mutations have been 
reported in the PRKAB1 gene. 
To be noted 
Note: Although PRKAB1 itself does not seem to be 
directly implicated in human disease, there is an 
indirect relationship between AMPKbeta and heart 
disease and cancer due to the implication of other 
subunits of the AMPK complex or to the implication f 
other related kinases: 
- AMPK in heart disease:  
Mutations at the PRAAG2 (encoding the gamma2 
subunit of AMP-activated protein kinase) causes 
glycogen overload, Wolff-Parkinson-White syndrome, 
arrhythmias, and heart failure. 
- AMPK in cancer:  
LKB1 is a serine/threonin kinase that phosphorylates 
and activates AMPK. Germ-line mutations at LKB1 
lead to the cancer-prone syndrome Peutz-Jeghers 
syndrome whereas somatic mutations are implicated in 
the development of non-small cell lung cancer. 
References 
Gao G, Fernandez CS, Stapleton D, Auster AS, Widmer J, 
Dyck JR, Kemp BE, Witters LA. Non-catalytic beta- and 
gamma-subunit isoforms of the 5'-AMP-activated protein 
kinase. J Biol Chem 1996;271:8675-8681. 
Mitchelhill KI, Michell BJ, House CM, Stapleton D, Dyck J, 
Gamble J, Ullrich C, Witters LA, Kemp BE. Posttranslational 
Modifications of the 5 -AMP-activated Protein Kinase beta 1 
Subunit. J Biol Chem 1997;272:24475-24479. 
Stapleton D, Woollatt E, Mitchelhill KI, Nicholl JK, Fernandez 
CS, Michell BJ, Witters LA, Power DA, Sutherland GR, Kemp 
BE. AMP-activated protein kinase isoenzyme family: subunit 
structure and chromosomal location. FEBS Lett 1997;409:452-
456. 
Thornton C, Snowden MA, Carling D. Identification of a novel 
AMP-activated protein kinase beta subunit isoform that is 
highly expressed in skeletal muscle. J Biol Chem 
1998;273:12443-12450. 
Warden SM, Richardson C, O'Donnell J Jr, Stapleton D, Kemp 
BE, Witters LA. Post-translational modifications of the beta-1 
subunit of AMP-activated protein kinase affect enzyme activity 
and cellular localization. Biochem J 2001;354:275-283. 
Hardie DG. Minireview: the AMP-activated protein kinase 
cascade: the key sensor of cellular energy status. 
Endocrinology 2003;144:5179-5183. 
Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä 
TP, Alessi DR, Hardie DG. Complexes between the LKB1 
tumor suppressor, STRADalpha/beta and MO25alpha/beta are 
upstream kinases in the AMP-activated protein kinase 
cascade. J Biol 2003;2:28. 
Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy 
response to control cell growth and survival. Cell 
2003;115:577-590. 
Li J, Jiang P, Robinson M, Lawrence TS, Sun Y. AMPK-beta1 
subunit is a p53-independent stress responsive protein that 
inhibits tumor cell growth upon forced expression. 
Carcinogenesis 2003;24:827-834. 
Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, 
Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, 
Kemp BE, Stapleton D. AMPK beta subunit targets metabolic 
stress sensing to glycogen. Curr Biol 2003;13:867-871. 
Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, 
Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. 
LKB1 is the upstream kinase in the AMP-activated protein 
kinase cascade. Curr Biol 2003;13:2004-2008. 
Woods A, Vertommen D, Neumann D, Turk R, Bayliss J, 
Schlattner U, Wallimann T, Carling D, Rider MH. Identification 
of phosphorylation sites in AMP-activated protein kinase 
(AMPK) for upstream AMPK kinases and study of their roles by 
site-directed mutagenesis. J Biol Chem 2003;278:28434-
28442. 
Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, 
Levine AJ. The regulation of AMPK beta1, TSC2, and PTEN 
expression by p53: stress, cell and tissue specificity, and the 
role of these gene products in modulating the IGF-1-AKT-
mTOR pathways. Cancer Res 2007;67:3043-3053. 
Sanchez-Cespedes M. A role for LKB1 gene in human cancer 
beyond the Peutz-Jeghers syndrome. Oncogene 2007 Jun 
18;[Epub ahead of print]. 
This article should be referenced as such: 
Sanchez-Cespedes M. PRKAB1 (protein kinase, AMP-
activated, beta 1 non-catalytic subunit). Atlas Genet Cytogenet 
Oncol Haematol. 2008;12(2):151-152.  
 
